Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.
Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR. Ginsburg AS, et al. Among authors: dorman se. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. doi: 10.1086/379328. Epub 2003 Nov 4. Clin Infect Dis. 2003. PMID: 14614666
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Dorman SE, et al. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30. Am J Respir Crit Care Med. 2009. PMID: 19406981 Clinical Trial.
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium. Dorman SE, et al. J Infect Dis. 2012 Oct 1;206(7):1030-40. doi: 10.1093/infdis/jis461. Epub 2012 Jul 30. J Infect Dis. 2012. PMID: 22850121 Clinical Trial.
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Savic RM, et al. Among authors: dorman se. Antimicrob Agents Chemother. 2014 Jun;58(6):3035-42. doi: 10.1128/AAC.01918-13. Epub 2014 Mar 10. Antimicrob Agents Chemother. 2014. PMID: 24614383 Free PMC article. Clinical Trial.
Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.
Parsons TL, Marzinke MA, Hoang T, Bliven-Sizemore E, Weiner M, Mac Kenzie WR, Dorman SE, Dooley KE. Parsons TL, et al. Among authors: dorman se. Antimicrob Agents Chemother. 2014 Nov;58(11):6747-57. doi: 10.1128/AAC.03607-14. Epub 2014 Sep 2. Antimicrob Agents Chemother. 2014. PMID: 25182637 Free PMC article. Clinical Trial.
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium. Dorman SE, et al. Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Am J Respir Crit Care Med. 2015. PMID: 25489785 Free PMC article. Clinical Trial.
154 results